MannKind reported $307.03M in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
Adma Biologics USD 236.62M 242K Dec/2024
BioCryst Pharmaceuticals USD 1.9M 3K Sep/2023
Eli Lilly USD 946.83M 354.23M Jun/2025
Halozyme Therapeutics USD 117.78M 259K Dec/2025
Insmed USD 214.26M 1.67M Dec/2025
Karyopharm Therapeutics USD 13K 0 Sep/2024
MacroGenics USD 63.26M 62.63M Sep/2025
MannKind USD 307.03M 303.99M Sep/2025
Merck USD 2.49B 15.79M Sep/2025
Minerva Neurosciences USD 1000 0 Sep/2024
Novavax USD 1.62M 211K Sep/2024
Novo Nordisk DKK 4.44B 3.99B Jun/2025
Pfizer USD 5.69B 1000K Sep/2025
Xencor USD 71.34M 46K Sep/2025